NATICK, Mass., Jan. 19, 2011 /PRNewswire/ — Boston
Scientific Corporation (NYSE: BSX) today announced that its
subsidiary, Boston Scientific Japan K.K., has reached an agreement
with Fukuda Denshi Co., Ltd. to market and sell its cardiac rhythm
management (CRM) devices and accessories throughout Japan.
Fukuda Denshi’s extensive sales resources, distribution
network and service capabilities will complement Boston
Scientific’s existing sales and marketing organization and allow
the Company to reach substantially more accounts and expand the
service it offers to its customers in Japan. Fukuda Denshi
will begin distributing Boston Scientific CRM products this
quarter.
“We are pleased to reach agreement with Fukuda Denshi to
distribute our CRM products in Japan,” said Maulik Nanavaty,
President of Boston Scientific Japan. “Our enhanced sales,
distribution and service capabilities will help us better serve
Japanese physicians and their patients while broadening our reach
and growing our market share in this important market. Fukuda
Denshi has been an established player in Japan for more than 70
years, with a proven track record and a long and successful history
of delivering results. We look forward to a successful
partnership with them.”
Boston Scientific is a leading developer of implantable devices
used to treat cardiac arrhythmias (abnormal heart rhythms), sudden
cardiac arrest and heart failure. The Company’s advanced
product portfolio includes pacemakers, implantable cardioverter
defibrillators (ICDs), cardiac resynchronization therapy
defibrillators (CRT-Ds), cardiac leads and patient management
systems.
About Fukuda Denshi
Founded in 1939, Fukuda Denshi is a global leader in the
research and development, manufacture and sale of medical
electronics equipment. With corporate headquarters in Tokyo,
the company supports direct sales and distributor networks
globally. Its annual revenues exceed $1 billion.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad
range of interventional medical specialties. For more
information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
“anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,”
“intend” and similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be
guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding new product launches and launch cadence, regulatory
approvals, clinical trials, product performance and competitive
offerings. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A Risk Factors in Quarterly
Reports on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this
document.
SOURCE
